Health Companies
Oasys Health ๐บ๐ธ 
Linda AI ๐ฎ๐ช 
Alithea Genomics ๐จ๐ญ 
Hippocratic AI ๐บ๐ธ 
Tucuvi ๐ช๐ธ 
Fluosphera ๐จ๐ญ 
Samantree Medical ๐ง๐ช 
Tozaro ๐ฌ๐ง 
Delphyr ๐ณ๐ฑ Latest Deals in Health
Sorcero has raised $42.5 million in Series B funding, led by NewSpring Growth and joined by Leawood Venture Capital and Blu Ventures, totaling $59 million raised. The company provides an AI platform for life sciences, addressing the adoption of advanced therapies in medical affairs and safety.
SORCEROInvestors: NewSpring Growth, Leawood Venture Capital, Blu Ventures
FUNCTION HEALTH
Cassidy Bio has raised $8 million in seed funding, led by Ahren Innovation Capital, with participation from Lool Ventures and 10D VC, along with backing from AstraZeneca and Merck KGaA. The company aims to revolutionize gene-editing therapy development through its AI-driven genomic foundation model.
CASSIDY BIOInvestors: Ahren Innovation Capital, Lool Ventures, 10D VC, AstraZeneca, Merck KGaA
Voio, a healthcare-focused AI company, has raised $8.6 million in a seed round led by Laude Ventures and The House Fund. The company is developing an AI-powered reading platform to enhance diagnostic accuracy and alleviate burnout among radiologists, addressing capacity challenges in medical imaging.
VOIOInvestors: Laude Ventures, The House Fund
Artios secured ยฃ87 million in a Series D funding round led by SV Health Investors, RA Capital Management, and Janus Henderson Investors. Founded in 2016, the Cambridge-based health tech company focuses on targeting DNA damage response in cancer treatment.
ARTIOSInvestors: SV Health Investors, RA Capital Management, Janus Henderson Investors
Cassidy Bio, a Tel Aviv-based biotechnology company focused on AI-driven genomic models for gene editing therapies, raised $8 million in seed funding. The round was led by Ahren Innovation Capital, with participation from Lool Ventures, 10D VC, and Via Aion Lab's venture seeding track from AstraZeneca and Merck KGaA.
Investors: Ahren Innovation Capital, Lool Ventures, 10D VC, Via Aion Lab's venture seeding track from AstraZeneca, Merck KGaA
Cellbyte, a Munich-based AI platform aimed at shortening pharmaceutical drug launch timelines, has secured $2.75 million in seed funding. The round was led by Frontline Ventures, with participation from Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels.
CELLBYTEInvestors: Frontline Ventures, Y Combinator, Pace Ventures, Saras Capital, Springboard Health Angels
GE HEALTHCARE
Ai Proteins, a Boston-based biotech company utilizing artificial intelligence to develop de novo medicines, raised $41.5 million in Series A funding led by Mission BioCapital and Santรฉ Ventures, with participation from existing investors. The funds will support the expansion of operations and R&D efforts.
AI PROTEINSInvestors: Mission BioCapital, Santรฉ Ventures
Manta Cares, a San Francisco-based digital health company improving the cancer experience, raised $5.4 million in seed funding led by Pear VC and Sozo Ventures, with participation from strategic angels like Dr. Stanley Marks. The funding aims to enhance support for cancer patients.
MANTA CARESInvestors: Pear VC, Sozo Ventures, Dr. Stanley Marks
Ember, a San Francisco-based provider of AI solutions for healthcare denial prevention, raised $4.3 million in seed funding from investors including Nexus Venture Partners and Y Combinator. The funds will be used to expand its go-to-market team and accelerate technology development.
EMBERInvestors: Nexus Venture Partners, Y Combinator
Thrivory, a NYC-based healthcare AI company, raised $3.5 million in equity and up to $25 million in credit funding, led by Redesign Health with additional support from Trinity Capital. The company addresses reimbursement delays for providers through instant claims settlement.
THRIVORYInvestors: Redesign Health, Trinity Capital
Munich-based AI platform Cellbyte raised $2.75 million in seed funding, led by Frontline Ventures with participation from Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels. The company accelerates drug launches for pharmaceutical firms, achieving six-figure ARR and contracts with major players like Bayer shortly after launch.
Investors: Frontline Ventures, Y Combinator, Pace Ventures, Saras Capital, Springboard Health Angels
Vahaticor has secured $23 million in a Series B funding round led by S3 Ventures, with participation from Intuitive Ventures and a strategic investor. The company is developing an a-flux reducer system to enhance myocardial perfusion for patients with coronary microvascular dysfunction, supporting early feasibility studies and engineering efforts.
VAHATICORInvestors: S3 Ventures, Intuitive Ventures
Lifordi Immunotherapeutics, a clinical-stage biotech company developing antibody-drug conjugates for autoimmune disorders, secured $112 million in funding led by Sanofi Ventures, with participation from Arch Ventures, 5AM Ventures, and Atlas Venture. The investment supports a Phase 1 study of LFD-200, targeting rheumatoid arthritis while minimizing glucocorticoid toxicity.
LIFORDI IMMUNOTHERAPEUTICSInvestors: Sanofi Ventures, Arch Ventures, 5AM Ventures, Atlas Venture
AI-STROKE
Vahaticor, a Santa Clara-based medtech company focused on cardiac care for coronary microvascular dysfunction, raised $23 million in Series B funding led by S3 Ventures, with participation from Intuitive Ventures. The funds will support enrollment and engineering development for their upcoming studies.
Investors: S3 Ventures, Intuitive Ventures
Captain T Cell, a biotech company specializing in TCR-T cell therapies for solid tumors, secured โฌ20 million in funding led by Springboard Health Angels and Pluton Asset Holding AG. This financing will advance its CTC127 program into phase I trials, addressing the urgent need for effective cancer treatments.
CAPTAIN T CELLInvestors: Springboard Health Angels, Pluton Asset Holding AG